1- (3- ((2- (dimethylamino)ethyl)carbamoyl)phenyl)- 3- (4- (bis(2- chloroethyl)amino)phenyl)urea

structure in first source

Also Known As:

BO-1055; ureidomustin

Networked: 2 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Amides: 2428
  - Urea: 15015
    - Phenylurea Compounds: 1
      - 1-(3-((2-(dimethylamino)ethyl)carbamoyl)phenyl)-3-(4-(bis(2-chloroethyl)amino)phenyl)urea: 2
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Aromatic Hydrocarbons: 291
      - Benzene Derivatives: 17
        Phenylurea Compounds: 1
        1-(3-((2-(dimethylamino)ethyl)carbamoyl)phenyl)-3-(4-(bis(2-chloroethyl)amino)phenyl)urea: 2
  - Halogenated Hydrocarbons: 42
    - Mustard Compounds: 3
      - Nitrogen Mustard Compounds: 2
        1-(3-((2-(dimethylamino)ethyl)carbamoyl)phenyl)-3-(4-(bis(2-chloroethyl)amino)phenyl)urea: 2

Experts

1.	Su, Tsann-Long: 2 articles (07/2016 - 09/2015)
2.	Ambati, Srikanth R: 1 article (07/2016)
3.	Chaudhry, Anisha: 1 article (07/2016)
4.	Lopes, Eloisi Caldas: 1 article (07/2016)
5.	Moore, Malcolm A S: 1 article (07/2016)
6.	Pera, Benet: 1 article (07/2016)
7.	Saxena, Ashish: 1 article (07/2016)
8.	Shieh, Jae-Hung: 1 article (07/2016)
9.	Wong, Elissa W P: 1 article (07/2016)
10.	Chou, Wen-Cheng: 1 article (09/2015)

Related Diseases

1.	Neoplasms (Cancer) 09/22/2015 - "Our study pinpoints that BO-1055 can be used for treating tumors that with deficient NER, HR, and MGMT DNA repair genes, or for synergistic therapy in tumors that DNA damage response have been suppressed. " 07/12/2016 - "BO-1055 induced more DNA double strand breaks and γH2AX expression in cancer cells compared to benign cells. " 07/12/2016 - "BO-1055 showed inhibition of tumor growth in A673 xenografts and caused tumor regression in cyclophosphamide resistant patient-derived Ewing sarcoma xenografts and A204 xenografts. "
2.	Osteosarcoma (Osteogenic Sarcoma) 07/12/2016 - "BO-1055 had potent activity (submicromolar IC50) against Ewing sarcoma and rhabdomyosarcoma, intermediate activity in DSRCT (IC50 = 2-3μM) and very weak activity in osteosarcoma (IC50 >10μM) cell lines. "
3.	Ewing Sarcoma (Sarcoma, Ewing) 07/12/2016 - "Combination of BO-1055 and irinotecan demonstrated synergism in Ewing sarcoma PDX models. " 07/12/2016 - "BO-1055 had potent activity (submicromolar IC50) against Ewing sarcoma and rhabdomyosarcoma, intermediate activity in DSRCT (IC50 = 2-3μM) and very weak activity in osteosarcoma (IC50 >10μM) cell lines. " 07/12/2016 - "BO-1055 showed inhibition of tumor growth in A673 xenografts and caused tumor regression in cyclophosphamide resistant patient-derived Ewing sarcoma xenografts and A204 xenografts. "
4.	Sarcoma (Soft Tissue Sarcoma) 07/12/2016 - "Potent activity on sarcoma cells and its relative lack of toxicity presents a strong rationale for further development of BO-1055 as a therapeutic agent." 07/12/2016 - "BO-1055 caused apoptosis and cell death in a concentration and time dependent manner in sarcoma cell lines. " 07/12/2016 - "BO-1055, a novel DNA cross-linking agent with remarkable low myelotoxicity shows potent activity in sarcoma models."
5.	Rhabdomyosarcoma 07/12/2016 - "BO-1055 had potent activity (submicromolar IC50) against Ewing sarcoma and rhabdomyosarcoma, intermediate activity in DSRCT (IC50 = 2-3μM) and very weak activity in osteosarcoma (IC50 >10μM) cell lines. "

Related Drugs and Biologics

1.	DNA (Deoxyribonucleic Acid)
2.	Cyclophosphamide (Cytoxan)
3.	Irinotecan (Camptosar)

Related Therapies and Procedures

1.	Therapeutics